Karriereverlauf von Sophia Paspal
Ehemalige bekannte Positionen von Sophia Paspal
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2015 | 01.01.2017 |
Dart NeuroScience LLC
 Dart NeuroScience LLC Pharmaceuticals: MajorHealth Technology Dart NeuroScience LLC develops drugs to improve memory. The private company is based in San Diego, CA. The CEO of the company is Kenneth E. Johns. | Corporate Officer/Principal | 01.01.2014 | 01.01.2015 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Sophia Paspal
| University of Minnesota | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| China | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Dart NeuroScience LLC
Dart NeuroScience LLC Pharmaceuticals: MajorHealth Technology Dart NeuroScience LLC develops drugs to improve memory. The private company is based in San Diego, CA. The CEO of the company is Kenneth E. Johns. | Health Technology |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
- Börse
- Insiders
- Sophia Paspal
- Erfahrung
